OpGen, Inc.

153 articles with OpGen, Inc.

• Key Publication of Clinical Study Demonstrates Unyvero Lower Respiratory Tract (LRT) Panel is Likely to Alter Antibiotic Management of Significant Numbers of Patients Presenting with Suspected Pneumonia

  9/2/2020

  OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.

• OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19

  8/20/2020

  - Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour - 100% Sensitivity and 97.3% Specificity demonstrated in isolated RNA  - Inclusion of PCR-Compatible Universal Lysis Buffer (PULB) in the kit as a workflow option allows labs to circumvent the need for extraction equipment and reagents GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) --

• OpGen Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/12/2020

  Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020 Strategic co-promotion partnership with Menarini Silicon Biosystems to market and sell Menarini’s COVID-19 related products Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular di

• OpGen Co-Markets COVID-19 Antibody Test Kit

  8/9/2020

  As disclosed in OpGen, Inc.’s July 13, 2020 press release, we have commenced marketing and promotion, on a non-exclusive basis, of certain products offered by Menarini Silicon Biosystems to infectious disease healthcare providers and researchers.

• OpGen to Provide Business Update and Financial Results for the Second Quarter 2020

  8/5/2020

  OpGen, Inc. announced that the Company will provide a business update and report its second quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, August 12, 2020.

• OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2020

  7/15/2020

  Preliminary Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020

• OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours

  6/9/2020

  Performance of the Unyvero HPN Panel for pneumonia proves to be strongly concordant (98.2%) compared to bacterial lower respiratory tract culture   Collaboration with Karolinska Institutet highlights critical need for rapid diagnostic tests, as one in four COVID-19 patients in the ICU had a bacterial co-infection Providing results in hours instead of days provides clinicians with early organism differential, including resistance marker information, allowing earlier treatment decisions and s

• OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections

  6/3/2020

  Project to utilize OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions

• OpGen CEO and Chairman of the Board Issue Letters to Stockholders - May 11, 2020

  5/11/2020

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, to issued two letters to stockholders from new OpGen CEO Oliver Schacht and Chairman of the Board William Rhodes.

• OpGen Reports First Quarter 2020 Financial Results and Provides Business Update

  5/7/2020

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, reported its stand-alone financial and operating results for the three months ended March 31, 2020 and provided a business update.

• OpGen to Provide Business Update and Financial Results for the First Quarter 2020

  4/27/2020

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020.

• OpGen Subsidiary Curetis GmbH and Karolinska Institutet Collaborate in Study of Bacterial Co-Infections in COVID-19 Pneumonia Patients

  4/21/2020

  Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections

• OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study

  4/16/2020

  Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs NGS-based testing reached 100% agreement with reference culture-based testing for 32 pathogen-drug pairs and 89% across all 129 pathogen-drug combinations evaluated The comprehensive study on NGS-based antibiotic susceptibility testing was based on 620 isolates from more than

• OpGen Announces Preliminary Unaudited Revenue and Cash Position for First Quarter 2020 and Provides Business Update

  4/14/2020

  OpGen, Inc. announced that total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019, excluding revenues from the Curetis businesses, which was acquired upon closing of the business combination on April 1, 2020.

• OpGen and Curetis Successfully Close their Business Combination Transaction

  4/1/2020

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that the business combination between Curetis and OpGen has successfully closed on April 1, 2020.

• OpGen Announces Shareholder Approval for Business Combination with Curetis

  3/30/2020

  OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that, following its Special Meeting of Shareholders held March 30, 2020, OpGen shareholders overwhelmingly voted to approve the proposed business combination with Curetis N.V. OpGen reported that 95% of the votes cast were voted to approve the business combination.

• OpGen Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update for OpGen and Curetis Group

  3/24/2020

  OpGen, Inc. (NASDAQ: OPGN), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, reported today its audited stand-alone financial and operating results for the three and 12 months ended December 31, 2019 and provided a business update.

• OpGen Provides Further Update on Shareholder Proxy Voting in Relation to the Business Combination with Curetis

  3/24/2020

  Shareholder proxy vote achieves quorum with 99% support for the transaction Final step in OpGen / Curetis business combination achieved pending results of Special Meeting GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today an update on shareholder proxy voting in relation to the business combination with Curetis.

• OpGen Data Predicting Phenotypic Antimicrobial Susceptibility Published in Diagnostic Microbiology & Infectious Disease Journal

  3/23/2020

  In an analysis of K. pneumoniae bacterial isolates, an overall agreement of 95.6% was observed between phenotypic antimicrobial susceptibility and genotypic prediction by OpGen’s Acuitas Lighthouse® platform using whole genome sequencing data

• OpGen Provides Update on Shareholder Proxy Voting in Relation to the Business Combination with CuretisShareholder proxy vote stands at 97% of the required quorum with support for the transaction at over 95%

  3/19/2020

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced an update on shareholder proxy voting in relation to the business combination with Curetis.